Arrowhead Pharmaceuticals (ARWR) Interest & Investment Income (2012 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Interest & Investment Income came in at $16.9 million in Q1 2026, up 75.44% YoY from $9.6 million in Q1 2025, and up 73.91% on a QoQ basis from $9.7 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Interest & Investment Income (2012 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 9 years of Interest & Investment Income data on file, last reported at $16.9 million in Q1 2026.
- Quarterly Interest & Investment Income rose 75.44% year-over-year to $16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.7 million (up 51.13% YoY) and the FY2025 annual result came in at $37.3 million, up 64.12% from the prior year.
- Interest & Investment Income grew to $16.9 million in Q1 2026, from $9.7 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $16.9 million in Q1 2026 to a low of $1.1 million in Q1 2022.
- A 5-year average of $6.2 million and a median of $6.2 million in 2024 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 332.64% in 2023, down 4.47% in 2023.
- Tracing ARWR's Interest & Investment Income over 5 years: stood at $2.7 million in 2022, then rose by 4.47% to $2.8 million in 2023, then surged by 171.31% to $7.6 million in 2024, then advanced by 27.6% to $9.7 million in 2025, then soared by 73.91% to $16.9 million in 2026.
- The last three Interest & Investment Income figures came in at $16.9 million (Q1 2026), $9.7 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 16.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.94 Mn |
| Mar 31, 2026 | 16.87 Mn |
| Dec 31, 2025 | 9.70 Mn |
| Sep 30, 2025 | 9.09 Mn |
| Jun 30, 2025 | 11.02 Mn |
| Mar 31, 2025 | 9.62 Mn |
| Dec 31, 2024 | 7.60 Mn |
| Sep 30, 2024 | 7.17 Mn |
| Jun 30, 2024 | 6.50 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 3.89 Mn |
| Jun 30, 2023 | 4.17 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 1.58 Mn |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 1.05 Mn |
| Mar 31, 2015 | 89,954.00 |
| Dec 31, 2014 | 23,774.00 |